Perspective Therapeutics, Inc. - 8-K Filing
Perspective Therapeutics announced interim clinical trial results for three programs—[212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359—that will be presented at the 2026 ASCO Annual Meeting. For [212Pb]VMT01 in melanoma, two confirmed responses were observed out of seven patients treated with monotherapy (29% response rate). The PSV359 program advanced to Cohort 3 without dose-limiting toxicities or treatment discontinuations due to adverse events. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CATX